



ASX Release

Anatara Annual General Meeting & Director Nominations

MELBOURNE, 29 September 2021: Anatara Lifesciences (ASX: ANR), a developer of evidence based solutions for gastrointestinal diseases in animals and humans, is pleased to announce

Anatara Lifesciences Limited's Annual General Meeting ("AGM") will be held at 11:00 a.m. AEST on Tuesday 16 November 2021.

One item of business at the AGM will be the election of Directors. The closing date for the receipt of nominations is Wednesday 6 October 2021. Nominations must be received at Anatara Lifesciences Limited's registered office no later than 5:00 p.m. AEST on the closing date.

--Ends--

This announcement is authorised by the Board, Anatara Lifesciences Limited.

For more information please contact:

General inquiries	
Steven Lydeamore CEO, Anatara Lifesciences Ltd +61 (0) 438 027 172 slydeamore@anatara.com	Eric Kuret Market Eye +61 (0) 417 311 335 eric.kuret@marketeye.com.au

About Anatara Lifesciences Ltd

Anatara Lifesciences Ltd (ASX:ANR) is developing and commercialising innovative, evidence-based solutions for gastrointestinal health where there is significant unmet need. Anatara is a life sciences company with expertise in developing products for human and animal health considerations. Anatara is focused on building a portfolio of human gastrointestinal health products, with lead product GaRP (Gastrointestinal ReProgramming) being a dietary supplement with a range of potential indications for the relief of gastrointestinal tract (GIT) symptoms and conditions. Underlying this product development program is our commitment to delivering real outcomes for patients and strong value for our shareholders.

Disclaimer

The information in this presentation does not constitute personal investment advice. The presentation is not intended to be comprehensive or provide all information required by investors to make an informed decision on any investment in Anatara Lifesciences Ltd, ACN 145 239 872 (Company). In preparing this presentation, the Company did not take into account the investment objectives, financial situation, and particular needs of any particular investor. Further advice should be obtained from a professional investment adviser before taking any action on any information dealt with in the presentation. Those acting upon any information without advice do so entirely at their own risk. Whilst this presentation is based on information from sources which are considered reliable, no representation or warranty, express or implied, is made or given by or on behalf of the Company, any of its directors, or any other person about the accuracy, completeness or fairness of the information or opinions contained in this presentation. No responsibility or liability is accepted by any of them for that information or those opinions or for any errors, omissions, misstatements (negligent or otherwise) or for any communication written or otherwise, contained or referred to in this presentation. Neither the Company nor any of its directors, officers, employees, advisers, associated persons or subsidiaries are liable for any direct, indirect or consequential loss or damage suffered by any person as a result of relying upon any statement in this presentation or any document supplied with this presentation, or by any future communications in connection with those documents and all of those losses and damages are expressly disclaimed. Any opinions expressed reflect the Company's position at the date of this presentation and are subject to change.

Anatara Lifesciences Limited Registered Office

Level 3, 62 Lygon Street, Carlton South, VIC, 3053, Australia

Administration and R&D

Suite 101, 55 Flemington Rd, North Melbourne, VIC 3051, Australia

Email info@anatara.com | Website anataralifesciences.com

